Lyka Labs Ltd

Lyka Labs Ltd

₹ 129 0.04%
22 Apr 1:02 p.m.
About

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]

Key Points

Business Overview:[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.

  • Market Cap 426 Cr.
  • Current Price 129
  • High / Low 144 / 88.5
  • Stock P/E
  • Book Value 20.6
  • Dividend Yield 0.00 %
  • ROCE 4.93 %
  • ROE -28.4 %
  • Face Value 10.0

Pros

  • Company has reduced debt.

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 9.25% over past five years.
  • Debtor days have increased from 50.1 to 79.0 days.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
26.81 24.26 49.44 73.89 35.57 35.19 27.49 25.53 17.82 22.24 22.88 27.99 32.56
20.80 18.02 19.54 28.27 22.55 22.59 21.18 20.50 15.61 18.94 20.24 23.82 25.69
Operating Profit 6.01 6.24 29.90 45.62 13.02 12.60 6.31 5.03 2.21 3.30 2.64 4.17 6.87
OPM % 22.42% 25.72% 60.48% 61.74% 36.60% 35.81% 22.95% 19.70% 12.40% 14.84% 11.54% 14.90% 21.10%
0.70 -0.50 0.47 -3.20 0.58 -2.27 0.95 0.98 -5.95 0.02 0.38 -0.18 0.54
Interest 6.59 6.37 6.93 5.57 4.64 2.99 2.91 3.03 3.08 2.85 1.35 1.19 1.28
Depreciation 2.12 2.02 2.13 3.52 2.24 9.46 3.59 3.62 3.47 3.47 3.47 3.59 2.84
Profit before tax -2.00 -2.65 21.31 33.33 6.72 -2.12 0.76 -0.64 -10.29 -3.00 -1.80 -0.79 3.29
Tax % 7.00% 159.25% 8.59% 16.98% 6.55% -607.08% 6.58% 46.88% -2.24% 0.00% -7.22% 22.78% 38.60%
-2.27 1.14 19.55 28.43 6.09 -15.07 0.60 -0.38 -10.42 -3.01 -1.85 -0.49 1.78
EPS in Rs -0.79 0.40 6.81 9.91 2.12 -5.25 0.21 -0.13 -3.63 -0.98 -0.56 -0.15 0.54
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
170 127 119 166 130 110 60 71 61 86 194 93 106
155 99 111 139 110 87 63 73 65 67 93 76 89
Operating Profit 15 28 8 28 20 23 -4 -2 -4 20 101 17 17
OPM % 9% 22% 7% 17% 16% 21% -6% -3% -6% 23% 52% 18% 16%
16 3 25 4 8 -2 4 1 -30 0 -4 -4 1
Interest 30 19 27 24 15 19 10 7 20 26 20 12 7
Depreciation 9 12 9 11 9 10 11 7 8 8 17 14 13
Profit before tax -8 0 -3 -3 4 -8 -20 -15 -62 -14 59 -13 -2
Tax % 0% 0% -45% -31% -5% 19% 5% 59% -1% 29% 35% 0%
-8 -1 -5 -5 4 -7 -19 -6 -63 -10 38 -13 -4
EPS in Rs -3.20 -0.33 -3.05 -2.29 1.67 -2.51 -6.14 -1.97 -21.10 -4.03 13.59 -4.30 -1.15
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: -3%
5 Years: 9%
3 Years: 15%
TTM: 0%
Compounded Profit Growth
10 Years: %
5 Years: 11%
3 Years: 22%
TTM: 90%
Stock Price CAGR
10 Years: 27%
5 Years: 35%
3 Years: 58%
1 Year: 23%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: -28%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 22 22 22 22 22 22 28 28 29 29 29 31 33
Reserves 51 44 30 20 22 16 21 14 -43 -54 -15 -3 35
Preference Capital 1 1 1 1 1 0 1 1 1 1 1 1
133 126 163 136 120 126 112 96 141 163 130 74 54
77 97 114 102 78 88 69 78 74 53 43 50 30
Total Liabilities 283 289 329 279 242 252 229 216 200 190 186 152 152
137 93 162 122 104 133 116 108 105 98 94 68 63
CWIP 8 47 22 27 30 24 28 31 28 26 18 16 17
Investments 6 6 0 0 0 0 0 0 0 0 0 0 0
132 143 145 130 107 94 85 77 68 66 74 67 71
Total Assets 283 289 329 279 242 252 229 216 200 190 186 152 152

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
1 11 89 27 12 31 11 27 5 9 79 9
12 5 -57 37 17 -13 -3 -4 -0 -0 -6 7
-16 -13 -26 -60 -30 -19 -10 -23 3 -12 -63 -22
Net Cash Flow -3 3 6 4 -1 -0 -3 -1 9 -3 10 -5

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2012 Mar 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 131 211 209 124 121 97 125 75 48 37 35 79
Inventory Days 57 99 91 77 56 90 139 65 69 41 56 68
Days Payable 158 236 363 220 218 266 301 216 192 141 96 91
Cash Conversion Cycle 30 73 -64 -18 -41 -79 -37 -75 -76 -63 -5 55
Working Capital Days 63 96 -106 -88 -75 -191 -456 -181 -156 -71 6 34
ROCE % 5% 10% 2% 10% 7% 9% -8% -5% -6% 10% 61% 5%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
19.88% 20.00% 20.04% 47.79% 47.80% 47.58% 47.58% 51.00% 54.58% 54.81% 54.81% 54.81%
3.50% 2.07% 1.13% 1.12% 0.76% 0.57% 0.37% 0.18% 0.17% 0.18% 0.17% 0.17%
0.47% 1.85% 0.47% 1.19% 3.99% 4.00% 4.00% 3.74% 0.41% 0.41% 0.62% 0.81%
76.15% 76.08% 78.36% 49.89% 47.45% 47.85% 48.05% 45.08% 44.84% 44.61% 44.41% 44.21%
No. of Shareholders 22,12020,67227,72026,22026,96928,43328,51526,82027,20226,65226,42225,717

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents